Johnson & Johnson (NYSE:JNJ) Shares Sold by Mine & Arao Wealth Creation & Management LLC.

Mine & Arao Wealth Creation & Management LLC. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 9.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,383 shares of the company’s stock after selling 254 shares during the period. Mine & Arao Wealth Creation & Management LLC.’s holdings in Johnson & Johnson were worth $345,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the third quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new position in shares of Johnson & Johnson in the third quarter worth $40,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Finally, Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $152.09 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock’s 50-day moving average is $147.61 and its two-hundred day moving average is $156.13. The firm has a market cap of $366.17 billion, a P/E ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 EPS. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.